CureVac appoints permanent CEO

Tuesday, 04. August 2020 14:55

CureVac AG announced on Tuesday that it appointed Dr. Franz-Werner Haas as the permanent chief executive officer (CEO).

Haas previously worked as the acting CEO and chief operating officer (COO) at CureVac after he joined the company in June 2012 from SYGNIS Pharma AG. Also, CureVac revealed the hiring of Dr. Igor Splawski as chief scientific officer, effective immediately. Splawski will lead the company's mRNA biology research.

In late July, CureVac filed for an initial public offering (IPO) in the United States, noting it plans to list on the Nasdaq exchange under the ticker CVAC.

Related Links: 
Breaking the News / MS